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Radiation therapy (RT) is utilised for the treatment of around half of all oncology patients during the course of their illness. Despite
great clinical progress in the rational deployment of RT, the underlying molecular basis for its efficacy and toxicity are currently
imperfectly understood. In this study, we took a biochemical approach to evaluate the potential role of key ionising radiation repair
proteins in the treatment outcomes of patients with severe acute or late RT side effects. Lymphoblastoid cell lines were established
from blood samples from 36 radiosensitive cases and a number of controls (the latter had had RT but did not develop significant
toxicity). The expression level and migration of key proteins from the nonhomologous end-joining (NHEJ) pathway was evaluated by
Western blot analysis on cases and controls. We did not observe any abnormalities in expression level or migration pattern of the
following NHEJ proteins in radiosensitive cancer cases: Ku70, Ku80, XRCC4, DNA Ligase IV. These important negative results
provide evidence that mutations that affect protein expression of these NHEJ components are unlikely to underlie clinical radiation
sensitivity.
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There is a range in the severity of normal tissue reactions observed
when cancer patients receive standard radiotherapy (RT) treat-
ment. Some individuals develop severe normal tissue reactions
such as small bowel damage following pelvic irradiation or
myelopathy following irradiation of the spinal cord. Normal tissue
RT tolerance is dependent on many factors including dose,
fractionation, the volume irradiated and individual variation in
radiation sensitivity (McKay and Peters, 1997). The doses
prescribed in current practice are largely based on the clinically
determined tolerance of the normal tissues in the radiation field,
and have evolved to limit the proportion of highly radiosensitive
adverse reactions to about 0.5–5% of cases, depending on factors
such as the end point under consideration (Norman et al, 1988).
If it were possible to identify these ionising radiation
(IR)-hypersensitive individuals in advance of therapy by the
use of effective predictive assays, their treatment could be
adjusted or changed and it might then be possible to escalate the
dose in the remaining patients (i.e. the great majority of
individuals). This would be expected to improve local tumour
control and cure rates.
Much evidence supports a genetic basis for the predisposition to
adverse normal tissue reactions after RT (McKay and Peters, 1997).
Dysfunction of genes and their protein products involved in the
sensing and response of cells to IR is therefore a potential
mechanism of adverse normal tissue reactions to RT. Various
approaches might be considered in attempts to unravel the
molecular basis of clinical radiosensitivity. These include screen-
ing candidate radiosensitivity genes for mutations (Leong et al,
2000; Severin et al, 2001), adopting functional genomics
approaches (e.g. using DNA microarrays) or, as adopted here,
screening for abnormalities in key candidate proteins.
DNA double-strand breaks (dsbs) are the most lethal form of
cellular DNA damage, and are major IR-induced DNA lesions
(Jeggo, 1998a). Therefore, genes involved in processing this type of
DNA lesion are excellent candidates for involvement in radiation
hypersensitivity, and could account for all or a proportion of
clinical RT hypersensitivity. In mammalian cells, the primary
mechanism for repairing dsbs is nonhomologous end-joining
(NHEJ) (Bryans et al, 1999). Genetic experiments indicate that the
Ku heterodimer (Ku70 and Ku80), XRCC4 (X-ray repair cross
complementing Chinese hamster ovary cell line) and DNA ligase
IV are required for efficient NHEJ in all eukaryotic species
examined so far (Jeggo, 1998a). Mutation of any one of these four
factors in both the budding yeast Saccharomyces cerevisiae
(Herrmann et al, 1998; Wilson et al, 1997) and in mammalian
cells (Frank et al, 1998; Gao et al, 1998a; Grawunder et al, 1998)
yield very similar phenotypes, the features of which include
defective DNA dsb repair and marked sensitivity to IR. In
mammalian cells, NHEJ also requires the catalytic subunit of
DNA-dependent protein kinase (DNA-PKCS) (Jeggo, 1998a).
However, an orthologue for this factor has not been found in the
fully sequenced genome of S. cerevisiae. Even in species with a
DNA-PKCS orthologue, mutation sometimes results in a less severe
phenotype than is observed for the other three components of the
NHEJ pathway (Gao et al, 1998b; Taccioli et al, 1998). Revised 7 January 2003; accepted 3 February 2003
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yGiven the radiation-sensitive phenotype displayed by mutants
defective in components of the NHEJ pathway, in multiple
eukaryotic species, we reasoned that these proteins were good
candidates for screening for abnormalities in radiation-sensitive
cancer patients. An abnormality in either the abundance of protein
production or its molecular mass may be because of mutations in
the corresponding gene, which could then be sequenced to identify
the corresponding nucleotide sequence variant. We carried out
and report here the results of Western blot analysis testing for
abnormalities of DNA ligase IV, XRCC4, Ku70 and Ku80 in a
cohort of severely radiosensitive cancer patients.
MATERIALS AND METHODS
Patients (cases and controls)
The patient cohort for this study comprised 36 radiation-sensitive
individuals referred by radiation oncologists at Peter MacCallum
Cancer Institute and several other centres within Australia. A
highly radiosensitive response was defined as a clinically overt and
unexpectedly severe radiation reaction (RTOG grades 3 and 4)
which occurred either acutely (during or within weeks of
completion of RT) or as a late adverse reaction (months to years
after completion of the RT course) (Figure 1). A number of cases
had controls (nonradiosensitive cancer patients) which were
matched for the following factors: sex, age, tumour type, stage
and grade and medications. The study was approved by the Peter
MacCallum Cancer Institute Ethics Committee and all patients
gave informed consent.
Lymphoblastoid cell lines
Blood was collected from each patient, from which lymphocytes
were isolated by Ficoll gradient centrifugation and then transfected
with Epstein–Barr virus to produce B-lymphoblastoid cell lines
(LCLs) (Neitzel, 1986). These transformed lymphocytes were
propagated as described (Leong et al, 2000) to provide an
accessible source of protein extracts.
SDS–polyacrylamide gel electrophoresis and Western
blotting analysis
Protein extracts were prepared from whole patient LCLs by
sonication in SDS sample buffer. Equal amounts of protein from
cases and controls (50mglane
 1 for ligase IV and XRCC4 gels;
15mglane
 1 for Ku70 gels; 5mglane
 1 for Ku80 gels) were loaded
onto a 10% SDS–PAGE gel and subjected to electrophoresis. For
Western blot analysis, separated proteins were transblotted onto
PVDF membrane (PolyScreen PVDF Transfer Membrane, NEN
Life Science Products, Boston, MA, USA) at a constant voltage of
100V for 2h in transfer buffer (25mM Tris, 190mM glycine, 20%
vv
 1 methanol), and the membrane blocked overnight in 10%
skim milk. The membrane was probed with anti-DNA ligase IV (at
1000-fold dilution), anti-XRCC4 (at 2500-fold dilution), anti-Ku70
(at 15000-fold dilution) or anti-Ku80 (at 15000-fold dilution)
antibodies as the primary antibody and horseradish peroxidase
conjugated goat anti-rabbit IgG as the secondary antibody (BIO-
RAD, CA, USA). Protein products were then visualised by
chemiluminescence (NEN Life Science Products, Boston, MA,
USA) and autoradiography. We used gamma tubulin antibody
(Wise et al, 2000) as an internal control to adjust for differences in
the amount of protein loaded in each lane. The anti-DNA ligase IV
antibody was raised against the C-terminal portion of the protein,
while antibodies to XRCC4, Ku70 and Ku80 were raised against the
full length of the protein. All primary antibodies were kindly
provided by Drs Susan Critchlow and Stephen Jackson (Wellcome/
CRC Institute, Cambridge, UK).
RESULTS
A total of 36 patients were examined for evidence of defects in
DNA ligase IV, XRCC4, Ku70 and Ku80 proteins using Western
blotting (Table 1). Bands of reported and appropriate size were
observed in all cases. Apparent molecular masses for DNA ligase
IV, XRCC4, Ku70 and Ku80 proteins were 96, 55, 70 and 80kDa,
respectively. The screening analysis revealed no evidence of
differences in expression level or of abnormal protein forms for
any of the four proteins in the 36 radiosensitive patients tested, as
compared to control patients (Figure 2). We would not expect any
variation in protein levels for these NHEJ proteins in control
patients.
DISCUSSION
In this study, we adopted a candidate protein approach to
ascertain whether abnormalities in proteins which collaborate in
the major dsb repair pathway, NHEJ, could be detected in cancer
patients who had suffered severe RT side effects in their normal
tissues. We therefore set out to determine whether defects in DNA
ligase IV, XRCC4, Ku70 or Ku80 could account at least for some
cases of radiation hypersensitivity. The screening analysis was
performed using Western blotting. This method should detect any
obvious differences in protein expression between radiosensitive
and control patients which may have resulted from mutations in
the corresponding genes. Despite an extensive analysis, we did not
detect any differences in expression in the cohort of patients
tested. We had also attempted to examine DNA-PKCS using
Western blotting. However, because of the large molecular mass of
DNA-PKCS (460kDa), initial attempts proved unsuccessful. Despite
efforts to optimize the procedure by varying the parameters for
electrophoresis and transblotting, we were unable to successfully
perform the Western analysis for DNA-PKCS.
Although we failed to identify any NHEJ protein defects, this
research is important for a number of reasons. First, studies such
as this have the potential to contribute to the understanding of the
mechanistic basis for clinical radiation hypersensitivity, which is
currently largely unknown. Second, numerous mammalian cell
lines and animals with naturally occurring or genetically
engineered mutations in NHEJ components manifest radiosensi-
tivity, including in the heterozygous state (see Introduction). The
latter might be expected to be most likely to be revealed in
Figure 1 Photograph showing an example of a severe late radiation
reaction. This patient (patient 8 in Table 1) developed severe fibrosis,
retraction and telangiectasia of the breast following routine postoperative
RT for breast cancer.
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yscreening studies such as reported here. Third, there is a precedent
for detection of abnormal ligase IV on Western analysis in a
radiosensitive individual: a leukaemia patient with fatal radio-
sensitivity has been identified to carry a mutation in a NHEJ
protein, with an abnormal pattern on Western analysis (Riballo
et al, 1999). Although this patient appears to have suffered a more
dramatic adverse radiation reaction compared to the patients in
our cohort, it is difficult to make direct comparisons. There is
currently no clear picture of the spectrum of severe adverse
radiation reactions that are seen in the clinical setting. One factor
determining the outcome of an adverse radiation reaction is the
organ that has been irradiated. For example, the consequences of a
severe reaction in skin (e.g. fibrosis) would be far less dramatic
than that seen in the spinal cord (e.g. paraplegia). This patient with
a mutation in ligase IV was a young child who had received
radiation to a developing brain. There are no similar patients in
our cohort who had received cranial irradiation for comparison.
We aimed to further evaluate this reported experience to
Table 1 Patient characteristics
Patient Tumour Radiotherapy schedule Adverse reaction
1 Carcinoma of breast 46Gy in 23 F plus boost 15Gy in 5 F to breast Severe fibrosis, retraction and telangiectasia. Rib fracture
2 Carcinoma of breast 46Gy in 23 F plus boost 15Gy in 5 F to breast Severe fibrosis and retraction
3 Carcinoma of breast 50Gy in 25 F to breast Severe fibrosis and telangiectasia
4 Carcinoma of breast 46Gy in 20 F to chest wall Severe fibrosis and telangiectasia
5 Carcinoma of breast 46Gy in 20 F to chest wall Severe fibrosis and rib fractures
6 Carcinoma of breast 46Gy in 20 F to chest wall Soft tissue necrosis
7 Carcinoma of breast 50Gy in 25 F to breast Severe acute moist desquamation. Severe fibrosis and
telangiectasia
8 Carcinoma of breast 50Gy in 25 F plus boost 10Gy in 5 F to breast Severe fibrosis, retraction and telangiectasia
9 Carcinoma of breast 18Gy in 9 F to breast (treatment terminated
prematurely)
Severe acute reaction with moist desquamation, erythema
and oedema
10 Carcinoma of breast 50Gy in 25 F plus boost 10Gy in 5 F to breast Severe fibrosis and telangiectasia
11 Carcinoma of breast 45Gy in 25 F plus boost 20Gy in 10 F to breast.
48Gy in 24 F to supraclavicular fossa and axilla
Severe fibrosis affecting breast, supraclavicular fossa and
axilla, causing excessive lymphoedema
12 Carcinoma of breast (bilateral) 50Gy in 25 F plus boost Severe acute reaction with moist desquamation, erythema
and oedema
10Gy in 5 F to chest wall
13 Carcinoma of breast 50Gy in 25 F plus boost 10Gy in 5 F to breast Severe acute reaction with erythema and oedema after
10Gy
14 Carcinoma of breast 46Gy in 23 F plus boost 15Gy in 5 F to breast Severe fibrosis, retraction and telangiectasia
15 Carcinoma of breast 46Gy in 23 F plus boost 15Gy in 5 F to breast Severe fibrosis and retraction
16 Carcinoma of breast 45Gy in 25 F plus boost 15Gy in 5 F to breast Severe acute reaction with moist desquamation and
oedema. Severe fibrosis, retraction and telangiectasia
17 Carcinoma of breast 28Gy in 14 F to breast (treatment terminated
prematurely)
Severe acute reaction with moist desquamation, erythema
and oedema
18 Carcinoma of tonsillar fossa 44Gy in 22 F plus boost 16Gy in 10 F Severe acute moist desquamation and mucositis requiring
nasogastric tube feeding for over 1 month
19 Carcinoma of cervix 45Gy in 25 F plus 30Gy to point A in a single
insertion
Small bowel damage requiring resection. Haemorrhagic
cystitis
20 Carcinoma of cervix 45Gy in 25 F plus 30Gy to point A in a single
insertion
Strictures of sigmoid colon and ureter requiring surgery
Peripheral neuropathy
21 Carcinoma of cervix 54Gy in 30 F plus 25Gy to point A in a single
insertion
Acute diarrhoea and bowel obstruction requiring surgical
resection
22 Carcinoma of cervix 50Gy in 25 F plus 25Gy to point A in a single
insertion
Severe small bowel damage
23 Carcinoma of anus 28Gy in 14 F (treatment terminated prematurely) Severe moist desquamation
24 Malignant melanoma 50Gy in 25 F to supraclavicular fossa Severe moist desquamation during 4th week of RT
25 Carcinoma of floor of mouth 58Gy in 29 F (treatment terminated prematurely) Severe acute mucositis
Late radionecrosis of mandible requiring resection
26 Malignant thymoma 50Gy in 25 F to chest Severe and prolonged acute oesophagitis for 6 weeks
27 Carcinoma of lung 60Gy in 30 F to chest Subacute pneumonitis
28 Carcinoma of lung 36Gy in 12 F Acute, marked confluent erythema of skin. Subacute
pneumonitis
29 Transitional cell carcinoma of urethra 50Gy in 25 F to pelvis Avascular necrosis of hip
30 Carcinoma of prostate 64Gy in 32 F to pelvis Radiation proctitis with PR bleeding requiring laser
treatment
31 Carcinoma of prostate 60Gy in 30 F to pelvis Radiation proctitis with severe PR bleeding
32 Carcinoma of prostate 66Gy in 33 F to pelvis Radiation proctitis with severe PR bleeding
33 Carcinoma of prostate 64Gy in 32 F to pelvis Radiation proctitis with severe PR bleeding
34 Carcinoma of prostate 66Gy in 33 F to pelvis Radiation proctitis with PR bleeding requiring laser
treatment
35 Carcinoma of prostate 64Gy in 32 F to pelvis Radiation proctitis with PR bleeding requiring laser
treatment
36 Carcinoma of prostate 64Gy in 32 F to pelvis Radiation proctitis with severe PR bleeding
Gy=gray; F=fractions.
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ydetermine its generalisability to other radiosensitive cancer
patients. Collectively, these considerations formed a logical
rationale for the present investigations.
Although a variety of factors could theoretically influence
radiosensitivity, strong evidence implicates a genetic basis for the
predisposition to adverse normal tissue RT reactions. In recent
years, realisation of a probable genetic basis for radiosensitivity
has led to searches for genetic aberrations that could be used as
predictive assays. Screening for heterozygous mutations in the
gene homozygously mutated in the cancer-prone, radiosensitivity
disorder, ataxia-telangiectasia (ATM: AT mutated) in radiosensi-
tive patients has been vigorously pursued during the past few
years. However, data from several studies suggest that ATM gene
defects are not a major cause of radiation hypersensitivity
(Appleby et al, 1997; Clarke et al, 1998; Hall et al, 1998; Ramsay
et al, 1998; Shayeghi et al, 1998; Oppitz et al, 1999). We have
previously reported the results of mutation analysis of BRCA1 and
BRCA2 cancer predisposition genes in a cohort of radiation-
hypersensitive cancer patients (Leong et al, 2000).
Of the many types of DNA damage that can occur, dsbs are a
critical event leading to cell death if the break remains unrepaired
or is repaired improperly. Studies with mammalian cells have
suggested that the majority of dsbs are rejoined by NHEJ. Studies
using IR-sensitive mutant rodent cells have identified five factors
involved in this process; Ku70, Ku80, XRCC4, DNA ligase IV and
DNA-PKCS. Further investigation of these mutants revealed that
these proteins were also required for V(D)J recombination, the
process in B and T cells which allows immunological diversity
during antibody and T-cell receptor production, indicating that
these two fundamental DNA transactions share common compo-
nents (Pergola et al, 1993).
Several murine and human models have highlighted the critical
role that all these factors play in DNA dsb repair. Targeted
disruption of the gene encoding DNA ligase IV leads to late
embryonic lethality and impaired V(D)J recombination in mice
(Barnes et al, 1998; Frank et al, 1998). Ligase IV-deficient
embryonic fibroblasts also show marked sensitivity to IR (Frank
et al, 1998). 180BR is a radiosensitive fibroblast cell line derived
from a leukaemia patient who over-responded to RT and
subsequently died of radiation morbidity. 180BR cells were shown
to harbour a homozygous missense mutation in the ATP binding
domain of human DNA ligase IV (Riballo et al, 1999). DNA ligase
IV mutations have also been identified recently in several patients
exhibiting developmental delay and immunodeficiency, and cell
lines derived from these patients exhibit pronounced radio-
sensitivity (O’Driscoll et al, 2001). XRCC4 forms a tight complex
with DNA ligase IV in mammalian cells. Recombinant XRCC4
protein stimulates DNA binding and the ligation activity of DNA
ligase IV in vitro (Grawunder et al, 1997). Mice with targeted
disruption of the gene encoding XRCC4 have growth defects,
premature senescence, impaired V(D)J recombination and marked
sensitivity to IR (Gao et al, 1998a). Ku has at least three separate
functions in end-joining DNA dsb repair that have been identified
in vitro. It generally facilitates end-joining by aligning DNA ends,
and it specifically recruits both XRCC4-ligase IV and DNA-PKCS to
DNA ends (Nick_McElhinny et al, 2000). Ku80-deficient ES cells
and pre-B-cell lines are hypersensitive to IR (Nussenzweig et al,
1997) and consistent with the radiation-hypersensitive phenotype
of the cell lines, Ku80 mutant mice also display extreme
radiosensitivity (Nussenzweig et al, 1997). Mice lacking Ku70 are
immunodeficient and growth retarded, and Ku70-deficient ES cells
have increased radiosensitivity, defective DNA end binding activity
and an inability to support V(D)J recombination (Gu et al, 1997a,
b). In mammalian cells, NHEJ also typically requires DNA-PKCS.
DNA-PKCS is a member of the phosphatidylinositol (PI) 3-kinase
family that is activated upon binding to DNA ends. Cells derived
from highly radiosensitive SCID mice have a DNA dsb repair
deficiency caused by a mutation in the DNA-PKCS gene. However,
there are circumstances where mutation of DNA-PKCS still allows
much greater levels of end-joining than are observed when Ku,
XRCC4 or ligase IV is mutated. For example, mice completely
deficient in DNA-PKCS can join signal end intermediates in V(D)J
recombination, and ES cells from such mice possess a normal level
of resistance to IR (Gao et al, 1998b; Taccioli et al, 1998). The
function of DNA-PKCS in NHEJ therefore may be more dispensable
than that of Ku, XRCC4 or ligase IV, depending on the organism,
cell type and molecular context of the ends to be joined
(Nick_McElhinny et al, 2000).
In summary, the involvement of DNA ligase IV, XRCC4, Ku70
and Ku80 in dsb repair, and the radiosensitive phenotype
Figure 2 Typical Western blot analysis of protein extracts from radiosensitive patients using (A) anti-DNA ligase IV, (B) anti-XRCC4, (C) anti-Ku70 and
(D) anti-Ku80 antibodies. There were no differences in expression for any of the four proteins between radiosensitive and control patients. Gamma-tubulin
was used as an internal control to adjust for differences in the amount of protein loaded in each lane (lower autoradiograph in each panel). P¼radiosensitive
patient, C¼control patient.
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ydisplayed by mouse and human mutants in these NHEJ
components, justified analysis of these proteins in our cohort of
radiation-hypersensitive patients. We screened a highly selected
group of cancer patients with severe adverse reactions to standard
RT for defects in four of the five major NHEJ components using
Western analysis: no defects were detected. These results suggest
that mutations that affect protein expression of these factors do
not account for most cases of clinical radiation hypersensitivity,
and that screening for abnormalities of these factors using Western
blotting might be unlikely to be useful for predicting clinical
response to RT. However, we have not completely excluded that
defects in the NHEJ pathway may contribute to clinical radio-
sensitivity. It is possible that mutational changes that confer
radiosensitivity but have no other easily detectable impact may be
missense or subtle mutations that may not affect dramatically
protein levels. Also, we have not excluded that defects in DNA-
PKCS might contribute to clinical radiosensitivity. Since mutations
of DNA ligase IV account for some instances of radiation
hypersensitivity, we are examining further radiosensitive indivi-
duals for abnormal DNA ligase IV protein expression. Ongoing
candidate gene/protein analyses in radiosensitive cancer patients
are expected to yield further examples of the range of molecular
defects causing human radiosensitivity.
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